Stéphane Bancel

Rule Changes

Led settlement decision

For four years, the question of whether Moderna owed billions for technology at the heart of its COVID-19 vaccine hung over the company. Less than a week before a jury trial was set to begin in Delaware, Moderna agreed to pay up to $2.25 billion to settle patent claims brought by Arbutus Biopharma and Genevant Sciences—accepting a court judgment that it infringed four patents and that those patents are valid. If the full amount is paid, it would be the largest disclosed patent settlement in pharmaceutical history, surpassing a $2.15 billion Pfizer-Takeda settlement in 2013.

Updated Mar 4

New Capabilities

Leading Moderna's oncology pipeline

Metastatic breast cancer typically kills most patients within five years. A small group of women vaccinated in a Duke University clinical trial two decades ago have defied that prognosis entirely—all remain alive today. Researchers discovered these survivors still carry specialized immune cells capable of recognizing their cancer, pointing to a mechanism that could make therapeutic cancer vaccines work reliably.

Updated Jan 31

New Capabilities

Positioning Moderna's cancer vaccine pipeline as core to post-pandemic strategy

Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit—until now. On January 20, 2026, Moderna and Merck reported that their personalized mRNA vaccine, combined with the immunotherapy Keytruda, cut the risk of melanoma recurrence or death by 49% at five years in a Phase 2b trial of 157 patients. The sustained result—identical to the three-year mark—suggests the vaccine permanently reprograms immune surveillance rather than offering temporary protection.

Updated Jan 25